Overview

* KORU Medical ( KRMD ) Q3 revenue grows 27% yr/yr, driven by strong international sales

* Company improves Q3 net loss by 51% yr/yr, adjusted EBITDA turns positive

* KORU raises full-year 2025 revenue guidance to $40.5 - $41.0 mln

Outlook

* KORU Medical ( KRMD ) raises full-year 2025 revenue guidance to $40.5 - $41.0 mln, from prior range of $39.5 - $40.5 mln

* Company reiterates full-year 2025 gross margin guidance of 61% - 63%

* Company expects positive cash flow from operations for full year 2025

Result Drivers

* INTERNATIONAL SALES - Strong international sales driven by strategic market supply and new patient starts

* DOMESTIC SALES DECLINE - Domestic sales impacted by distributor inventory adjustments

* PHARMA COLLABORATIONS - New pharmaceutical collaborations expected to expand patient reach

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$800,00

Income 0

Q3 Gross 60.20%

Margin

Q3 $7.10

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for KORU Medical Systems Inc ( KRMD ) is $6.00, about 37.8% above its November 11 closing price of $3.73

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)